The aim of this study is to evaluate the effects of Levodopa-Benserazide drug combination on periodontal status and salivary cytokine levels in patients with Parkinson's disease. The study includes four groups: Parkinson's patients with periodontitis, periodontally healthy Parkinson's patients, participants without Parkinson's with periodontitis, and periodontally healthy participants without Parkinson's. Clinical periodontal parameters (Plaque Index, Gingival Index, Bleeding on Probing, Pocket Depth, and Clinical Attachment Loss) will be recorded. Unstimulated saliva samples will be collected to analyze the levels of TNF-alpha, RANTES, IL-10, IL-13, Total Oxidant Status (TOS), Total Antioxidant Status (TAS), and Malondialdehyde (MDA).
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Salivary Inflammatory Cytokine
Timeframe: Day 1
Salivary Inflammatory Cytokine
Timeframe: Day 1
Salivary Inflammatory Cytokine
Timeframe: Day 1
Salivary Inflammatory Cytokine
Timeframe: Day 1
Salivary Oxidative Stress Levels
Timeframe: Day 1
Salivary Oxidative Stress Levels
Timeframe: Day 1
Salivary Oxidative Stress Levels
Timeframe: Day 1